Autumn Research Update Meeting 2025
Our 2025 Autumn Research Update Meeting will take place once again at the renowned Royal Society of Medicine (RSM), Wimpole Street, London, on Monday 10 November, where guests can look forward to an engaging agenda featuring the latest updates from our funded research. Theme: Revolutionising...
Learn more
The Ambroxol Results
The new year has started with some pleasing clinical trial news for the Parkinson’s community: The results of the “Ambroxol in Disease Modification in Parkinson Disease” (AiM-PD study) have been published. This is a clinically available drug that is used for the treatment of respiratory issues, which researchers are re-purposing for Parkinson’s based on […]
The Bydureon phase 3 trial: supplementary substudies
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to be supporting two sub-studies within the important Bydureon phase 3 trial (Exenatide-PD 3)
Ambroxol in Parkinson’s: results of phase 2 trial published
Cure Parkinson’s, in partnership with Van Andel Institute and the John Black Charitable Foundation, is proud to announce the publication of the results of the phase 2 clinical trial that evaluated the safety and tolerability of ambroxol to treat Parkinson’s. The trial background In late…
Phase 2 respiratory drug for Parkinson’s has promise
13 January 2020 Results published today in The Journal of the American Medical Association (JAMA) Neurology Cure Parkinson’s is delighted to announce the publication of the results of a phase 2 clinical trial evaluating ambroxol as a potential treatment to slow the progression of Parkinson’s….
Cure Parkinson’s – 15 Years
2020 is a milestone year for Cure Parkinson’s. It marks our 15th year of investing in pioneering Parkinson’s research and a chance to reflect on the advances we have achieved within the Parkinson’s arena. We are not celebrating this 15th anniversary as such, but rather…